国联民生证券承销保荐有限公司 关于成都康华生物制品股份有限公司 调整部分募集资金投资项目实施进度的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"或"保荐 机构"）作为成都康华生物制品股份有限公司（以下简称"康华生物"、"公司"） 首次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等法律法规和规范性文件的规定，对康华生物调整部分募集资金投资项目实施进 度相关事项进行审慎核查，核查意见如下： 一、募集资金基本情况 公司经中国证券监督管理委员会证监许可[2020]521号《关于核准成都康华 生物制品股份有限公司首次公开发行股票的批复》核准，首次公开发行人民币普 通股（A股）1,500.00万股，每股发行价为人民币70.37元，募集资金总额为人民 币105,555.00万元，扣除各项发行费用人民币7,457.70万元后，募集资金净额为人 民币98,097.30万元。募集资金到位情况业经立信会计师事务所（特殊普通合伙） 于2020年 ...

成都康华生物制品股份有限公司 第三届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第十二 次会议通知于2025年12月27日以专人送达、邮件等方式向全体董事发出，会议于 2025年12月29日以通讯表决的方式召开；本次会议由董事长刘大伟先生召集并主 持，会议应出席董事11人，实际出席董事11人。本次会议的召集和召开程序符合 《中华人民共和国公司法》《成都康华生物制品股份有限公司章程》等有关规定， 会议合法、有效。 二、 董事会会议审议情况 （一）审议通过《关于调整部分募集资金投资项目实施进度的议案》 证券代码：300841 证券简称：康华生物 公告编号：2025-072 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调 整部分募集资金投资项目实施进度的公告》（公告编号：2025-073）。 议案表决结果：同意票 11 票，反对票 0 票，弃权票 0 票。 三、 备查文件 1、公司第三届董事会第十二次会议决议； ...

成都康华生物制品股份有限公司（以下简称"公司"）于近日接到控股股东 上海万可欣生物科技合伙企业（有限合伙）（以下简称"万可欣"）的通知，获 悉万可欣将其持有的公司部分股份办理了解除质押业务，具体情况如下： 二、控股股东及其一致行动人股份累计质押情况 证券代码：300841 证券简称：康华生物 公告编号：2025-074 成都康华生物制品股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏,并就其保证承担个别和连带的责任。 公司将持续关注股东质押情况，并按照相关规定及时履行信息披露义务，敬 请广大投资者注意投资风险。 四、备查文件 1、中国证券登记结算有限责任公司出具的《证券质押及司法冻结明细表》； 根据王振滔先生与万可欣签署的《表决权委托协议》，王振滔先生将其持有 的公司 1,050.3517 万股股份（占公司总股本的 8.0829%）的表决权委托给万可欣 行使，根据《上市公司收购管理办法》及深圳证券交易所的相关规定，王振滔先 生与万可欣为一致行动人。 截至本公告披露日，控股股东万可欣及其一致行动人王振滔先生所持股份质 ...

Core Insights - The Shanghai Biopharmaceutical Industry M&A Fund has completed three investments since its establishment in March 2025, achieving 34% of its investment target within nine months [1] - The fund, with an initial scale of 5 billion yuan, is part of the Shanghai municipal state-owned capital fund matrix and aims to enhance strategic, leveraged, and platform functions while adhering to market-oriented operations [1] Investment Strategies - The fund employs three investment strategies: 1. Controlling acquisitions to gain majority stakes in companies 2. Active minority investments to significantly influence company governance and improve investor confidence 3. Restructuring based on pipelines and assets [2] - The completed investments include assisting Shanghai Pharmaceuticals in acquiring Shanghai Hengrui, strategic equity investment in MicroPort Medical, and equity investment in Kanghua Biotech [2] Market Context - The vaccine industry is currently experiencing a downturn, with the industry index dropping approximately 80% from its peak in 2022, attributed to supply-demand imbalances and overcapacity [3] - The fund's post-investment integration for Kanghua Biotech focuses on enhancing corporate governance, optimizing marketing structures, adjusting R&D strategies, and initiating capital operations [3] Policy Environment - The forum highlighted the importance of M&A as a tool for resource optimization and a pathway for deepening reforms in state-owned enterprises, with local state-owned listed companies showing significant progress in M&A activities since 2024 [4] - The supportive policy environment for M&A has led to a notable increase in transactions within the technology sector [5]

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Core Points - A situation report was released by the Guizhou Tongzi County Health Bureau regarding a complaint about a rabies vaccine being replaced at the Hai School Street Community Health Service Center [1] - The incident involved a nurse scanning the wrong code, leading to a public apology from the center's director [1] - The health bureau issued disciplinary actions against the center's director and deputy director, including a one-month performance salary deduction, and three-month deductions for the nurses involved [1] Summary by Sections Incident Details - On December 17, three individuals received rabies vaccinations at the Hai School Street Community Health Service Center [4] - The vaccines administered included a freeze-dried rabies vaccine produced by Chengdu Kanghua Biological Products Co., priced at 310 yuan per dose, while another vaccine from Shandong Yidu Biotechnology Co. was priced at 80 yuan per dose [4] - The vaccination information recorded in the system did not match the vaccine received by the patient, Zhao [4] Response and Actions Taken - Following the incident, the center's director, Ma, apologized to the family of Zhao for the error [5] - The health bureau confirmed that there was no actual replacement of the vaccine, and the correct vaccine was administered to Zhao [4] - The center provided a commitment letter to the family, assuring responsibility for any adverse reactions that may occur [6]

Group 1 - The health bureau of Tongzi County, Zunyi, Guizhou, issued a situation report regarding a public complaint about a vaccine substitution at a community health service center [1] - An investigation revealed that on December 17, a patient named Zhao received a rabies vaccine from Chengdu Kanghua Biological Products Co., Ltd., priced at 310 yuan per dose [2] - A nurse mistakenly entered the tracking code of a different vaccine from Shandong Yidu Biotechnology Co., Ltd., which costs 80 yuan per dose, leading to discrepancies in the vaccination information system [2]

Group 1 - The incident involved a vaccination error at a community health service center, where a nurse mistakenly scanned the wrong code, leading to an apology from the center's director to the affected family [3] - The health bureau conducted an investigation and issued disciplinary actions, including a one-month salary deduction for the center's director and deputy director, and a three-month salary deduction for the nurses involved [3] - The health bureau plans to implement stricter internal management regulations across all medical institutions in the county to prevent similar incidents in the future [3] Group 2 - The vaccine in question was a freeze-dried human rabies vaccine produced by Chengdu Kanghua Biological Products Co., priced at 310 yuan per dose [2] - As of December 17, the community health service center had a remaining inventory of 65 doses of the vaccine, with 9 doses recorded on December 16 [2] - The vaccination incident occurred on December 17, with the affected individual receiving one dose of the rabies vaccine [2]

Investigation Summary - On December 17, a patient named Zhao visited the Hai School Street Community Health Service Center for a rabies vaccine after being bitten by a dog. The vaccine administered was from Chengdu Kanghua Biological Products Co., priced at 310 yuan per dose. However, a nurse mistakenly scanned the packaging of a different vaccine from Shandong Yidu Biotechnology Co., which costs 80 yuan per dose, leading to a discrepancy in the vaccination information system [2][3] - On December 16, the inventory showed 67 doses of the vaccine from Shandong Yidu, and on December 17, after two doses were administered, 65 doses remained. For Chengdu Kanghua's vaccine, there were 9 doses on December 16, and after Zhao's vaccination, 8 doses remained. The investigation confirmed that there was no actual change of medication [2] Handling Measures - Following the incident, the director of the health center, Ma, apologized to Zhao's family for the error. The health bureau issued a reprimand to both the director and the deputy director, deducting one month's performance salary. The nurses involved received criticism and a deduction of three months' performance salary [3] - The health bureau plans to strengthen internal management regulations across all medical institutions in the county to prevent similar incidents in the future [4]

Core Viewpoint - The biopharmaceutical sector experienced a rise of 0.76% on December 17, with ST Weiming leading the gains. The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1]. Group 1: Stock Performance - ST Weiming (002581) closed at 7.49, with a gain of 5.05% and a trading volume of 58,400 shares, amounting to a transaction value of 43.46 million yuan [1]. - Wendi Pharmaceutical (688488) closed at 14.59, up 4.36%, with a trading volume of 56,400 shares and a transaction value of 80.52 million yuan [1]. - Kanghua Biological (300841) closed at 75.75, increasing by 2.98%, with a trading volume of 13,700 shares and a transaction value of 102 million yuan [1]. - Wan Ze Co., Ltd. (000534) closed at 23.31, up 2.24%, with a trading volume of 226,800 shares and a transaction value of 519 million yuan [1]. - Other notable stocks include Kang Le Wei Shi (920575) at 10.28 (+1.88%), Gan Li Pharmaceutical (603087) at 66.80 (+1.71%), and Anke Biological (300009) at 9.67 (+1.58%) [1]. Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 344 million yuan from institutional investors, while retail investors experienced a net inflow of 441 million yuan [2]. - The capital flow for ST Weiming showed a net inflow of 14.06 million yuan from institutional investors, while retail investors had a net outflow of 645.75 million yuan [3]. - Kanghua Biological had a net inflow of 13.85 million yuan from institutional investors, with retail investors also experiencing a net outflow of 625.92 million yuan [3].